Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Elon Musk’s SpaceX Acquires xAI in Historic Deal Uniting Space and Artificial Intelligence 
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
CK Hutchison Unit Launches Arbitration Against Panama Over Port Concessions Ruling 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
Denso Cuts Profit Forecast Amid U.S. Tariffs and Rising Costs 
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Boeing Signals Progress on Delayed 777X Program With Planned April First Flight 
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock 
Novo Nordisk Warns of Profit Decline as Wegovy Faces U.S. Price Pressure and Rising Competition 
NEWARK, Calif., Aug. 28, 2017 -- Depomed Inc. (NASDAQ:DEPO) today announced that it has been selected to join the Collaborative for Effective Prescription Opioid Policies (CEPOP) a diverse group of over 70 stakeholders creating and advancing policies and educational initiatives aimed at reducing opioid abuse and promoting treatment options for those living with pain or confronting addiction.
“We are pleased to be joining a well-respected organization that shares our commitment to reducing prescription opioid misuse as well as highlighting the ethical and responsible prescribing and use of treatment options for those living with pain,” said Arthur Higgins, President and Chief Executive Officer of Depomed. “We look forward to engaging with this unique group of patient, family advocacy, public health, prescriber, research and supply chain organizations to develop and implement strategies to address responsible opioid use while recognizing the needs of patients in pain. At Depomed, it is clear to us that tackling these issues requires collaboration among all stakeholders, and we view this partnership with CEPOP as an important addition to our ongoing and future activities aimed at highlighting the responsible prescribing and use of opioids.”
About the Collaborative for Effective Prescription Opioid Policies (CEPOP)
Launched in January of 2015, the Collaborative for Effective Prescription Opioid Policies (CEPOP) brings together a broad array of stakeholders interested in reducing opioid medication abuse, misuse, and diversion. Specifically, CEPOP supports a comprehensive and balanced public policy agenda that reduces abuse and promotes treatment options, both for those living with pain and confronting addiction. CEPOP’s advocacy is focused on driving actions in the public sector that develop and deploy evidence-based solutions to these challenges. For more information visit https://cepoponline.org/
About Depomed
Depomed is a leading specialty pharmaceutical company focused on enhancing the lives of the patients, families, physicians, providers and payors we serve through commercializing innovative products for pain and neurology related disorders. Depomed markets six medicines with areas of focus that include mild to severe acute pain, moderate to severe chronic pain, neuropathic pain, migraine and breakthrough cancer pain. Depomed is headquartered in Newark, California. To learn more about Depomed, visit www.depomed.com.
INVESTOR AND MEDIA CONTACT: Christopher Keenan VP, Investor Relations and Corporate Communications 510-744-8000 [email protected]
